|
Mutation Information
|
Mutation Site
|
T215F |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.K219E+rt.T215F+rt.D67N |
Literature Information
|
PubMed PMID
|
30544247
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2019 |
|
Journal
|
The Journal of antimicrobial chemotherapy |
|
Title
|
Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance. |
|
Author
|
Geretti AM,White E,Orkin C,Tostevin A,Tilston P,Chadwick D,Leen C,Sabin C,Dunn DT,UK HIV Drug Resistance Database and UK CHIC Study. |
|
Evidence
|
Most (203 of 269, 75.5%) had singleton TAMs, commonly a revertant of T215Y or T215F (112 of 269, 41.6%). Over a median of 2.5 years of follow-up, 834 of 6599 (12.6%) subjects experienced viraemia (HIV-1 RNA >50 copies/mL). The adjusted HR for viraemia was 2.17 with PI/b versus NNRTI-based therapy (95% CI 1.88-2.51;P < 0.001).
|
|
|